Clinical characteristics and outcomes of nonsteroidal anti-inflammatory drug-related heart failure in real-world Japanese practice: a retrospective cohort study.
{"title":"Clinical characteristics and outcomes of nonsteroidal anti-inflammatory drug-related heart failure in real-world Japanese practice: a retrospective cohort study.","authors":"Masakazu Miura, Tomoaki Ienaga, Fumiaki Nakao, Takeshi Ueyama, Yasuhiro Ikeda","doi":"10.1007/s00380-025-02603-w","DOIUrl":null,"url":null,"abstract":"<p><p>Although nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for musculoskeletal pain, their use in patients with heart failure (HF) is discouraged because of risks of fluid retention and worsening disease. Nevertheless, in older patients, NSAIDs are still prescribed by non-cardiologists. We conducted a single-center retrospective cohort study of patients aged ≥ 65 years who were hospitalized for acute decompensated HF at Yamaguchi Prefectural General Medical Center between January 2016 and January 2022. Patients were classified as NSAIDs-related HF if NSAIDs use for ≥ 1 week before admission was identified through pharmacist review. As part of comprehensive cardiac rehabilitation, all patients received self-management guidance on medications, including NSAIDs avoidance. Multivariate Cox proportional hazards models were applied to assess associations with clinical outcomes. Among 801 patients, 64 (8.0%) were classified as NSAIDs-related HF and 737 (92.0%) as NSAIDs-unrelated HF. NSAIDs-related HF cases more frequently represented first-time HF hospitalizations. For the primary endpoint of all-cause mortality or HF readmission, the NSAIDs-related group showed a trend toward improved outcomes, although the difference did not reach statistical significance (hazard ratio [HR] 0.569, 95% confidence interval [CI] 0.289-1.118; p = 0.102). In contrast, the incidence of the secondary endpoint, major adverse cardiac and cerebrovascular events (MACCE), was significantly lower in the NSAIDs-related group (HR 0.404, CI 0.178-0.917; p = 0.030). NSAIDs-related HF accounted for a modest proportion of new HF hospitalizations in older patients. After standard management and NSAIDs discontinuation, outcomes were comparable to those of other HF patients, with a trend toward fewer adverse events. These findings likely reflect differences in patient background and comprehensive rehabilitation rather than a direct protective effect of discontinuation.</p>","PeriodicalId":12940,"journal":{"name":"Heart and Vessels","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart and Vessels","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00380-025-02603-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Although nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for musculoskeletal pain, their use in patients with heart failure (HF) is discouraged because of risks of fluid retention and worsening disease. Nevertheless, in older patients, NSAIDs are still prescribed by non-cardiologists. We conducted a single-center retrospective cohort study of patients aged ≥ 65 years who were hospitalized for acute decompensated HF at Yamaguchi Prefectural General Medical Center between January 2016 and January 2022. Patients were classified as NSAIDs-related HF if NSAIDs use for ≥ 1 week before admission was identified through pharmacist review. As part of comprehensive cardiac rehabilitation, all patients received self-management guidance on medications, including NSAIDs avoidance. Multivariate Cox proportional hazards models were applied to assess associations with clinical outcomes. Among 801 patients, 64 (8.0%) were classified as NSAIDs-related HF and 737 (92.0%) as NSAIDs-unrelated HF. NSAIDs-related HF cases more frequently represented first-time HF hospitalizations. For the primary endpoint of all-cause mortality or HF readmission, the NSAIDs-related group showed a trend toward improved outcomes, although the difference did not reach statistical significance (hazard ratio [HR] 0.569, 95% confidence interval [CI] 0.289-1.118; p = 0.102). In contrast, the incidence of the secondary endpoint, major adverse cardiac and cerebrovascular events (MACCE), was significantly lower in the NSAIDs-related group (HR 0.404, CI 0.178-0.917; p = 0.030). NSAIDs-related HF accounted for a modest proportion of new HF hospitalizations in older patients. After standard management and NSAIDs discontinuation, outcomes were comparable to those of other HF patients, with a trend toward fewer adverse events. These findings likely reflect differences in patient background and comprehensive rehabilitation rather than a direct protective effect of discontinuation.
尽管非甾体抗炎药(NSAIDs)广泛用于肌肉骨骼疼痛,但由于存在液体潴留和疾病恶化的风险,不鼓励在心力衰竭(HF)患者中使用。然而,在老年患者中,非甾体抗炎药仍由非心脏病专家开处方。我们对2016年1月至2022年1月在山口县综合医疗中心因急性失代偿性心衰住院的年龄≥65岁的患者进行了一项单中心回顾性队列研究。如果通过药师审查确定患者在入院前使用非甾体抗炎药≥1周,则将患者分类为非甾体抗炎药相关心力衰竭。作为全面心脏康复的一部分,所有患者都接受药物自我管理指导,包括避免使用非甾体抗炎药。应用多变量Cox比例风险模型评估与临床结果的相关性。801例患者中,64例(8.0%)为非甾体抗炎药相关性HF, 737例(92.0%)为非甾体抗炎药相关性HF。非甾体抗炎药相关的HF病例更多地代表了首次HF住院。对于全因死亡率或心衰再入院的主要终点,非甾体抗炎药相关组表现出预后改善的趋势,但差异未达到统计学意义(风险比[HR] 0.569, 95%可信区间[CI] 0.289-1.118; p = 0.102)。相反,次要终点主要心脑血管不良事件(MACCE)在非甾体抗炎药相关组的发生率显著降低(HR 0.404, CI 0.178-0.917; p = 0.030)。非甾体抗炎药相关心力衰竭在老年患者新发心力衰竭住院中占适度比例。在标准管理和停用非甾体抗炎药后,结果与其他HF患者相当,不良事件减少。这些发现可能反映了患者背景和全面康复的差异,而不是停药的直接保护作用。
期刊介绍:
Heart and Vessels is an English-language journal that provides a forum of original ideas, excellent methods, and fascinating techniques on cardiovascular disease fields. All papers submitted for publication are evaluated only with regard to scientific quality and relevance to the heart and vessels. Contributions from those engaged in practical medicine, as well as from those involved in basic research, are welcomed.